Report
Rayhan Ahmed

Equity Note on Beximco Pharmaceuticals Limited (BXPHARMA)

Beximco Pharmaceuticals Limited (BXPHARMA) is a leading manufacturer and seller of generic pharmaceutical formulation products for both domestic and international markets. The company produces over 300 generic medicines, which are available in more than 500 different presentations, covering key therapeutic classes such as antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, gastrointestinal etc. Additionally, the company manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. The company exports its generic pharmaceutical products to 68 countries, including highly regulated markets like the US and Europe.

Underlying
Beximco Pharmaceuticals Ltd

Provider
EBL Securities Ltd.
EBL Securities Ltd.

EBL Securities Ltd. (EBLSL) is one of the fastest growing full-service institutional brokerage companies in Bangladesh. On top of our expertise and achievements, we take pride in our strong commitment towards excellent client services and development of the Bangladesh capital markets.

EBLSL is a fully owned subsidiary of Eastern Bank Limited (EBL), one of the leading private commercial banks of Bangladesh. EBLSL is one of the TOP-10 brokerage companies of Bangladesh.

We have unwavering faith in the potential of Bangladesh. We also believe that an efficient, vibrant and transparent capital market can strongly contribute to the overall development of Bangladesh. Bangladesh is currently at the initial stage of capital market growth, and we are committed to assist the entry of early movers into a growth-oriented, vibrant, nascent emerging market.

EBLSL has developed a disciplined approach towards providing capital market services. The foundation for our business is a strong commitment towards market experience & professionalism, investment knowledge, market intelligence and research services.

Analysts
Rayhan Ahmed

Other Reports on these Companies
Other Reports from EBL Securities Ltd.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch